Abstract 

Hyperinsulinemia (HI) is a common endocrine metabolic disorder in obesity and is closely associated with cardiovascular disease. This study aims to investigate the effects of progressive weight reduction on HI and cardiovascular risk factors.
Methods

We enrolled 68 patients with overweight or obesity. Body composition assessments, clinical indicator sampling and a 75g-oral glucose tolerance test were conducted at baseline and after 12-month weight loss to assess HI and insulin sensitivity. And the people were divided into four groups based on the percent of weight loss (< 10 %, ~20 %, ~30 %, > 30 %) to study the remission of HI and changes in body composition and cardiovascular risk factors.

Results

A total of 66 participants were studied at the end. Progressive weight loss significantly reduced plasma glucose and insulin (P< 0.001, Pfor trend< 0.001) and did not progressively reduce cardiovascular risk factors (Pfor trend< 0.001). The greater the percentage of weight loss, the greater the remission rate of insulin resistance and hyperinsulinemia (Pfor trend< 0.001), which reaches 100% when weight loss exceeds 30%. After adjusting for factors such as age, gender, and medication usage, remission of HI was still associated with progressive weight loss.

Conclusion

With progressive weight loss, people with overweight or obesity experienced further improvements in glycemic outcomes, body compositions, HI and insulin resistance.

Keywords: hyperinsulinemia, obesity, Insulin resistance, weight loss, body composition

References:

1. Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res.2020;126(11):1477–1500. doi:10.1161/CIRCRESAHA.120.316101.
2. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol.2021;9(6):373–392. doi:10.1016/S2213-8587(21)00045-0.
3. Zeng Q, Li N, Pan XF, Chen L, Pan A. Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol. 2021;9(6):393–405. doi:10.1016/S2213-8587(21)00047-4.
4. Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11–20. doi:10.1016/j.cmet.2021.12.012.
5. Perdomo CM, Cohen RV, Sumithran P, Clément K, Frühbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401(10382):1116–1130. doi:10.1016/S0140-6736(22)02403-5.
6. Erion KA, Corkey BE. Hyperinsulinemia: a cause of obesity? Curr Obes Rep. 2017;6(2):178–186. doi:10.1007/s13679-017-0261-z.
7. Kolb H, Kempf K, Röhling M, Martin S. Insulin: too much of a good thing is bad. BMC Med. 2020;18(1):224. doi:10.1186/s12916-020-01688-6.
8. Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 2021;45(3):285–311. doi:10.4093/dmj.2020.0250.
9. van Vliet S, Koh HCE, Patterson BW, et al. Obesity is associated with increased basal and postprandial β-cell insulin secretion even in the absence of insulin resistance. Diabetes. 2020;69(10):2112–2119. doi:10.2337/db20-0377.
10. Yue Z, Qian L, Jin Y, et al. Hyperinsulinemia influences the short-term efficiency of laparoscopic sleeve gastrectomy for patients with obesity and insulin resistance. Diabetes Metab Syndr Obes. 2023;16:1745–1753. doi:10.2147/DMSO.S411440.
11. Williams KJ, Wu X. Imbalanced insulin action in chronic overnutrition: clinical harm, molecular mechanisms, and a way forward. Atherosclerosis. 2016;247:225–282. doi:10.1016/j.atherosclerosis.2016.02.004.
12. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7(2):95–96. doi:10.1016/j.cmet.2007.12.009.
13. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405. doi:10.1016/S0140-6736(21)01919-X.
14. Grams J, Garvey WT. Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action. Curr Obes Rep. 2015;4(2):287–302. doi:10.1007/s13679-015-0155-x.
15. Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(10):545–555. doi:10.1038/s41574-020-0381-5.
16. Page MM, Johnson JD. Mild suppression of hyperinsulinemia to treat obesity and insulin resistance. Trends Endocrinol Metab. 2018;29(6):389–399. doi:10.1016/j.tem.2018.03.018.
17. Semlitsch T, Stigler FL, Jeitler K, Horvath K, Siebenhofer A. Management of overweight and obesity in primary care—a systematic overview of international evidence-based guidelines. Obes Rev. 2019;20(9):1218–1230. doi:10.1111/obr.12889.
18. Ko GJ, Rhee CM, Kalantar-Zadeh K, Joshi S. The effects of high-protein diets on kidney health and longevity. J Am Soc Nephrol. 2020;31(8):1667–1679. doi:10.1681/ASN.2020010028.
19. Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334–1359. doi:10.1249/MSS.0b013e318213fefb.</
20. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellitus. 2021;13(4):315–409.
21. Park SY, Gautier JF, Chon S. Assessment of insulin secretion and insulin resistance in human. Diabetes Metab J.2021;45(5):641–654. doi:10.4093/dmj.2021.0220.
22. Tao LC, Ni XJ, Ting WT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68. doi:10.1186/s12933-022-01511-x.
23. Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–1730. doi:10.1056/NEJMoa2028198.
24. Fogarasi A, Gonzalez K, Dalamaga M, Magkos F. The impact of the rate of weight loss on body composition and metabolism. Curr Obes Rep. 2022;11(2):33–44. doi:10.1007/s13679-022-00470-4.
25. Ashtary-Larky D, Ghanavati M, Lamuchi-Deli N, et al. Rapid weight loss vs. slow weight loss: which is more effective on body composition and metabolic risk factors? Int J Endocrinol Metab. 2017;15(3):e13249. doi:10.5812/ijem.13249.
26. Stiegler P, Cunliffe A. The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss. Sports Med. 2006;36(3):239–262. doi:10.2165/00007256-200636030-00005.
27. Beals JW, Kayser BD, Smith GI, et al. Dietary weight loss-induced improvements in metabolic function are enhanced by exercise in people with obesity and prediabetes. Nat Metab. 2023;5(7):1221–1235. doi:10.1038/s42255-023-00829-4.
28. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23(4):591–601. doi:10.1016/j.cmet.2016.02.005.
29. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486. doi:10.2337/dc10-2415.
30. Templeman NM, Skovsø S, Page MM, Lim GE, Johnson JD. A causal role for hyperinsulinemia in obesity. J Endocrinol. 2017;232(3):R173–R183. doi:10.1530/JOE-16-0449.
31. Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity: beyond “calories in, calories out.” JAMA Intern Med. 2018;178(8):1098–1103. doi:10.1001/jamainternmed.2018.2933.
32. Gastaldelli A. Measuring and estimating insulin resistance in clinical and research settings. Obesity. 2022;30(8):1549–1563. doi:10.1002/oby.23503.
33. Jensen SBK, Juhl CR, Janus C, et al. Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity. 2023;31(4):977–989. doi:10.1002/oby.23715